MedWatch

Novo CFO: Obesity market is difficult to predict

Although there is a market for weight loss treatments, and Novo Nordisk has already experienced huge demand for obesity drug Wegovy, the market still needs to be developed over coming years. For this reason, Novo Nordisk’s 2025 predictions are considerably lower than the analyst consensus.

Karsten Munk Knudsen, CFO of Novo Nordisk | Photo: Novo Nordisk / PR

While equity analysts predict that Novo Nordisk’s obesity drug sales will reach DKK 40bn (USD 5.9bn) in 2025, the company itself is only forecasting 2025 sales of ”over DKK 25bn (USD 3.7bn, ed.),” CFO Karsten Munk Knudsen tells Danish business daily Børsen.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs